Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 6/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504293 | 0.84 | HDAC1 (0.56) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL30151702 | 0.84 | GLS (0.52) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL8279661 | 0.84 | POLB (0.53) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL1111369 | 0.84 | GLS (0.52) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL8342682 | 0.84 | GLS (0.55) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL30069429 | 0.84 | GLS (0.55) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL13981921 | 0.84 | GLS (0.55) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL1165088 | 0.84 | GLS (0.55) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL16181822 | 0.84 | GLS (0.55) | GLSBRD4CREBBPKDM4ANAMPT | |
| SCHEMBL6285264 | 0.82 | CTSS (0.56) | GLSBRD4CREBBPKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| CN-1441783-A | Drug containing dicyanopyridine derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | GLS 156/4885BRD4 1457/4885CREBBP 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.